Determining the exact reasons underlying the differential effects of DHODH inhibitors on the CD8+ T cell response in our tumor studies versus the work in autoimmunity, however, will require further investigation including detailed studies of how BRQ directly or indirectly affects CD8+ T cell biology. Here, CD8A is linked to neoplasm.